Verseon Unveils New Blockchain Technology

Tuesday, September 18, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

FREMONT, California, September 18, 2018 /PRNewswire/ --

Blockchain initiative will enable medical and pharma companies to

fund and accelerate life-saving developments 

Verseon today unveils transformative blockchain technology for tokenized securities, developed by its wholly owned subsidiary, BlockRules Ltd. Since its founding in 2002,

Verseon's mission remains to develop disruptive technologies and products that advance global health. As part of this goal, the company is challenging traditional drug development funding models through the process of tokenization of securities.

BlockRules technology supports the sale, launch, and trading of securities on a public blockchain complete with multijurisdictional regulatory compliance integrated and enforced directly on the blockchain. This breakthrough permits fully regulated, secure, and transparent support of securities, including decentralized trading.

Current blockchain technology has the potential to transform the global investment landscape. To accomplish that, token offerings need to comply with existing security regulations if they are to become ubiquitous. The technology developed by BlockRules is designed to overcome these regulatory hurdles.

"We founded Verseon with the goal of developing new technologies to advance the discovery and development of new medicines," said Adityo Prakash, CEO of Verseon. "By democratizing investment access with blockchain technology, we will change the way new medicines and other life-science innovations are funded and how the resulting proceeds are shared."

BlockRules Ltd. plans to offer its technology to innovative companies ready to embrace the rapidly developing blockchain community.  By bringing regulatory certainty to the blockchain, BlockRules aims to provide the global investment community with safer and more relevant opportunities for investment.

"Recent advances in the blockchain space have the potential to narrow the gap between innovative companies and investors," said Neil Woodford, founding partner of Woodford Investment Management*. "Verseon's innovations in this space address some of the traditional choke points in capital flow and should lead to a more efficient market."

About BlockRules Ltd. 

BlockRules Ltd., a wholly owned subsidiary of Verseon, is a blockchain technology company supporting the sale, launch and trading of securities. By enforcing multijurisdictional regulatory compliance directly on the blockchain, the company facilitates issuance and decentralized trading that is secure, transparent and verifiable. BlockRules Ltd. handles the registration of investor KYC ("know your customer") information for its products and is providing this service to prospective investors at https://www.blockrules.com.

About Verseon 

Verseon Corporation (http://www.verseon.com ) (AIM: VSN) is developing disruptive life-science technology to advance global health. The clinical-phase Company is using its proprietary, computational drug discovery platform paired with a comprehensive in-house chemistry and biology workflow to build a growing drug development pipeline. Through its wholly owned subsidiary BlockRules Ltd., Verseon is also pioneering blockchain technology for regulated securities.

*Woodford Investment Management is a shareholder in Verseon

For further information, please contact    

Verseon Corporation: http://www.verseon.com Sebastian Wykeham: +1-(510)-225-9000

Arden Partners (NOMAD and Joint Broker) Ruari McGirr / Maria Gomez De Olea: +44-(0)-20-7614-5900

Cantor Fitzgerald Europe (Joint Broker) Marc Milmo / Phil Davies: +44-(0)-20-7894-7000

For financial and business media enquiries, please contact

Buchanan Communications Ltd (PR Advisers) Henry Harrison-Topham / Jamie Hooper: +44-(0)-20-7466-5000

For trade and pharma media enquiries, please contact

Vane Percy & Roberts Simon Vane Percy: +44-(0)-1737-821-890

SOURCE Verseon Corporation



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store